ArticleCureus2025
Real-World Treatment Outcomes in the First and Subsequent Coronavirus Disease 2019 (COVID-19) Hospital Clusters.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe experienced 10 coronavirus disease 2019 (COVID-19) hospital clusters between November 2020 and September 2023 and retrospectively examined whether the introduction of hospital cluster countermeasures improved patient prognosis.
methodsWe compared the first hospital cluster, in which infection prevention measures were insufficient, vaccines were not introduced, and antiviral drugs were not available (Phase 1), and the second or subsequent hospital clusters, when the abovementioned measures were improved (Phase 2).
resultsIn Phase 2, the number of COVID-19 patient deaths within 30 days, infection rate in patients who shared a room with an infected patient, and infection rate among medical workers were reduced. Survival rates within 30 days did not differ significantly between Phases 1 and 2. In Phase 2, the survival rate was higher in females than in males and in groups treated with ensitrelvir and molnupiravir than in those treated with remdesivir.
conclusionsCountermeasures against hospital clusters require comprehensive measures, such as infection prevention, vaccination, rapid diagnosis, and antiviral drug administration. Antiviral drugs may shorten hospital clusters by rapidly suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.